MedTrace Logo

Patient Satisfaction and Quality of Life Impact - PecFent®

NCT01693328 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2014-01-15

No results posted yet for this study

Summary

National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of cancer pain conditions.

• Study objectives include assessment of early treatment satisfaction.

Conditions

  • Breakthrough Cancer Pain

Interventions

DRUG

PecFent® (fentanyl) nasal spray

Sponsors & Collaborators

  • Archimedes Development Ltd

    lead INDUSTRY

Principal Investigators

  • Alain Serrie, MD · Head of Pain Federation - Palliative Medicine Lariboisiere Hospital, Paris France

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2014-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01693328 on ClinicalTrials.gov